BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30701029)

  • 1. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.
    Padgaonkar A; Rechkoblit O; Vasquez-Del Carpio R; Pallela V; Venkata Subbaiah D; Cosenza SC; Baker SJ; Ramana Reddy MV; Aggarwal A; Reddy EP
    Oncotarget; 2018 Dec; 9(102):37753-37765. PubMed ID: 30701029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
    Divakar SK; Ramana Reddy MV; Cosenza SC; Baker SJ; Perumal D; Antonelli AC; Brody J; Akula B; Parekh S; Reddy EP
    Leukemia; 2016 Jan; 30(1):86-93. PubMed ID: 26174628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
    Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
    Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
    Chon HJ; Bae KJ; Lee Y; Kim J
    Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
    Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
    Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
    Manni S; Pesavento M; Spinello Z; Saggin L; Arjomand A; Fregnani A; Quotti Tubi L; Scapinello G; Gurrieri C; Semenzato G; Trentin L; Piazza F
    Front Cell Dev Biol; 2022; 10():935023. PubMed ID: 36035991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
    Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
    Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of CK2 in acute and chronic leukemias.
    Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
    Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
    Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
    Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
    Shishodia S; Amin HM; Lai R; Aggarwal BB
    Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy.
    Shimura T; Kakuda S; Ochiai Y; Kuwahara Y; Takai Y; Fukumoto M
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):540-8. PubMed ID: 21398050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.
    Gowda C; Soliman M; Kapadia M; Ding Y; Payne K; Dovat S
    Adv Biol Regul; 2017 Aug; 65():16-25. PubMed ID: 28623166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.